Gold prices steady above $3,400/oz on rate cut bets; PCE data awaited
Investing.com -- Qiagen (NYSE:QGEN) reported strong second-quarter result, driven by strong demand for its diagnostic solutions and improved profitability, and raised its full-year sales outlook.
Net sales rose 7% to $534 million, or 6% at constant exchange rates (CER), beating its prior guidance for at least 5% CER growth.
Adjusted diluted EPS came in at $0.60, also ahead of the company’s target of at least $0.60 CER.
Qiagen said adjusted operating income margin improved to 29.9%, up 1.5 percentage points from the year-ago period.
Growth was led by an 11% CER increase in diagnostic solutions, supported by a 41% jump in QIAstat-Dx sales and 11% growth in QuantiFERON, along with gains in companion diagnostics.
The company now expects full-year net sales growth of 4–5% CER, up from about 4% previously. It maintained its adjusted EPS outlook of approximately $2.35 CER.